A vaccine being tested in human patients by Dublin-based company United Neurosciences has shown promising results, according to a statement released by the company.
96 percent of patients responded to the drug and showed improved cognition and a lower level of beta-amyloid, the toxic plaque that accumulates in Alzheimer’s patients and the target of the vaccine. Read more from Being Patient.
